Results 101 to 110 of about 34,994 (236)

PTEN homozygous deletion is a negative prognostic factor in tumor treating fields‐treated glioblastoma, IDH wildtype patients

Brain Pathology, EarlyView.
In a molecularly confirmed cohort of 64 newly diagnosed, TTFields‐treated glioblastomas, IDH‐wildtype, homozygous PTEN deletion was associated with markedly shorter overall survival (368 vs. 603 days) and remained an independent adverse prognostic factor.
Jakob Nückles, Claudius Jelgersma, Christin Siewert, Brendan Osberg, Simone Schmid, Arend Koch, Eilís Perez, Daniel Teichmann, Martin Misch, Anna‐Gila Karbe, Susanne Ukrow, Patrick N. Harter, Ruth M. Stassart, Peter Vajkoczy, Julia Onken, David Capper   +15 more
wiley   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

The FGFR inhibitor Rogaratinib reduces microglia reactivity and synaptic loss in TBI

Frontiers in Immunology
BackgroundTraumatic brain injury (TBI) induces an acute reactive state of microglia, which contribute to secondary injury processes through phagocytic activity and release of cytokines.
Rida Rehman, Rida Rehman, Albrecht Froehlich, Florian olde Heuvel, Lobna Elsayed, Tobias Boeckers, Tobias Boeckers, Markus Huber-Lang, Cristina Morganti-Kossmann, Cristina Morganti-Kossmann, Francesco Roselli, Francesco Roselli   +11 more
doaj   +1 more source

The Role of Fibroblast Growth Factor Receptors Inhibitors in Bladder Cancer [PDF]

Journal of Urologic Oncology
Dysregulation of fibroblast growth factor (FGF)-receptor (FGFR) signaling, which is implicated in various oncogenic processes, including tumor proliferation, survival, migration, invasion, and angiogenesis, has been identified as a critical factor in ...
Ho Kyung Seo, Eui Hyun Jung, Sora Yang, Hye Won Lee   +3 more
doaj   +1 more source

Downregulation of KRTAP2‐3 Suppresses Proliferation and Tumor Formation of Oral Cancer Cells via Inactivation of KRAS Signals

Cancer Science, EarlyView.
KRTAP2‐3 drives OSCC progression by sustaining both mesenchymal and proliferative properties through KRAS signaling. Loss of KRTAP2‐3 induces MET, suppresses KRAS pathway activation, and markedly reduces tumor cell proiferation and tumor formation as illustarted in Figure.
Qianqian Miao, Zhijun Huang, Kazuki Takahashi, Haruka Ibi, Kohei Miyazono, Katarzyna A. Podyma‐Inoue, Tetsuro Watabe   +6 more
wiley   +1 more source

FGFs/FGFRs-dependent signalling in regulation of steroid hormone receptors – implications for therapy of luminal breast cancer

Journal of Experimental & Clinical Cancer Research, 2019
Stromal stimuli mediated by growth factor receptors, leading to ligand-independent activation of steroid hormone receptors, have long been implicated in development of breast cancer resistance to endocrine therapy.
Dominika Piasecka, Marcin Braun, Kamila Kitowska, Kamil Mieczkowski, Radzislaw Kordek, Rafal Sadej, Hanna Romanska   +6 more
doaj   +1 more source

LAMC2+ Epithelial Cells Drive Bladder Cancer Progression and Predict Immunotherapy Response via SERPINB3/STAT3/CD44 Axis

Cancer Science, EarlyView.
This study identified LAMC2+ epithelial cells through single‐cell sequencing and found that high expression of LAMC2 is associated with the malignant progression of bladder cancer. HdWGCNA and transcriptome sequencing revealed the SerpinB3/STAT3/CD44 axis. Diosmetin was selected as a potential LAMC2 inhibitor.
Yutong Chen, Yunzhong Jiang, Zezhong Yang, Minxuan Jing, Wentai Wu, Jiale He, Lu Wang, Minghai Ma, Yaodong Zhang, Min Wang, Jianpeng Li, Yuanchun Pu, Bingliang He, Yanjia Liu, Kaibo Mi, Hang Liu, Mengzhao Zhang, Jinhai Fan   +17 more
wiley   +1 more source

Prognostic value of FGFR gene amplification in patients with different types of cancer: a systematic review and meta-analysis.

PLoS ONE, 2014
BackgroundFibroblast growth factor receptor (FGFR) gene amplification has been reported in different types of cancer. We performed an up-to-date meta-analysis to further characterize the prognostic value of FGFR gene amplification in patients with cancer.
Jinjia Chang, Xinyang Liu, Shanshan Wang, Zhe Zhang, Zheng Wu, Xiaowei Zhang, Jin Li   +6 more
doaj   +1 more source

Integrated Analysis of HER2 Expression and ERBB2 Alterations in Bladder Cancer

Cancer Science, EarlyView.
Integrated analysis of 445 bladder cancers showed that HER2 membrane expression and ERBB2 amplification are distinct features. HER2 expression overlapped with NECTIN4 expression, whereas ERBB2 amplification was enriched in the LumU subtype and associated with poor prognosis.
Kensuke Hirosuna, Kazuki Nishimura, Moritoshi Sakamoto, Satoshi Tokushige, Keita Nakamori, Tomohisa Matsunaga, Yuki Yoshikawa, Takeshi Tsutsumi, Ryoichi Maenosono, Takuya Tsujino, Masahiko Ajiro, Haruhito Azuma, Akihide Yoshimi, Kazumasa Komura   +13 more
wiley   +1 more source

532 Evaluating fibroblast growth factor receptor (FGFR) pathway mRNA expression and protein activation in cholangiocarcinoma tumors

Journal of Clinical and Translational Science
Objectives/Goals: Personalized cancer therapy based on genomic testing is advancing patient care. Genomic alterations in fibroblast growth factor receptor (FGFR) predict response to FGFR inhibitors; however, the role of RNA expression and protein ...
Leah Stein, Julie W. Reeser, Michele R. Wing, Eric Samorodnitsky, Anoosha Paruchuri, Amy Smith, Thuy Dao, Zachary Risch, Emanuel F. Petricoin, Sameek Roychowdhury   +9 more
doaj   +1 more source